World's Best Scientists 2026 revealed!
Jan B. Vermorken

Jan B. Vermorken

D-Index & Metrics

Medicine

D-Index
106
Citations
47345
World Ranking
6457
National Ranking
74

Overview

Jan B. Vermorken is affiliated with the University of Antwerp in Belgium and has contributed extensively to the field of medicine, with a particular focus on oncology. Their research spans several subfields including oncology, otorhinolaryngology, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, and surgery.

The scientist's work covers multiple main topics related to cancer studies. These include:

  • Head and Neck Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Head and Neck Surgical Oncology
  • Lung Cancer Research Studies
  • Cancer-related gene regulation

Vermorken has published in various venues with higher frequency in journals such as:

  • Frontiers in Oncology
  • Cancers
  • Oral Oncology
  • The Oncologist
  • International Journal of Radiation Oncology*Biology*Physics

Frequent collaborators in their research include:

  • Petr Szturz
  • Marc Peeters
  • Filip Lardon
  • An Wouters
  • Hannah Zaryouh

Notable recent publications by Jan B. Vermorken include:

  • De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies, 2020, Journal of Clinical Oncology
  • SARS-CoV-2 and cancer: Are they really partners in crime?, 2020, Cancer Treatment Reviews
  • Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic, 2020, Oral Oncology
  • Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma, 2021, Medicinal Research Reviews
  • The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies, 2021, Frontiers in Immunology

Best Publications

  • Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

    Jan B. Vermorken;Ricard Mesia;Fernando Rivera;Eva Remenar

  • Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

    Jan B. Vermorken;Eva Remenar;Carla Van Herpen;Thierry Gorlia

  • Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

    Jan B. Vermorken;José Trigo;Ricardo Hitt;Piotr Koralewski

  • Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial

    J. Baptist Trimbos;Ignace Vergote;Giorgio Bolis;Jan B. Vermorken

  • European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

    E A Eisenhauer;W W ten Bokkel Huinink;K D Swenerton;L Gianni

  • Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

    Jan B Vermorken;Anke M E Claessen;Harm van Tinteren;Helen E Gall

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)

    N. S. Reed;C. Mangioni;H. Malmström;G. Scarfone

  • 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

    A du Bois;M Quinn;T Thigpen;J Vermorken

  • International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

    J Baptist Trimbos;Mahesh Parmar;Ignace Vergote;David Guthrie

  • Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

    Jan B Vermorken;Jan Stöhlmacher-Williams;Irina Davidenko;Lisa Licitra

  • Advanced epithelial ovarian cancer: 1998 consensus statements.

    J. S. Berek;K. Bertelsen;A. Du Bois;M. F. Brady

  • Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

    Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner

  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    Jean Pascal H Machiels;Robert I. Haddad;Jérôme Fayette;Lisa F. Licitra

  • Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

    J P Neijt;W W ten Bokkel Huinink;M E van der Burg;A T van Oosterom

  • Optimal treatment for recurrent/metastatic head and neck cancer

    J. B. Vermorken;P. Specenier

  • Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)

    Gordon J. S. Rustin;Michael Quinn;Tate Thigpen;Andreas du Bois

  • Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck A phase III study of the EORTC Head and Neck Cancer Cooperative Group

    M. Clavel;J. B. Vermorken;F. Cognetti;P. Cappelaere

  • Taxanes: A New Class of Antitumor Agents

    M. T. Huizing;V. H. Sewberath Misser;R. C. Pieters;W. W. ten Bokkel Huinink

  • European-Canadian randomized trial of Paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

    Elizabeth A. Eisenhauer;Wim W. ten Bokkel Huinink;Kenneth D. Swenerton;Luca Gianni

Frequent Co-Authors

H.M. Pinedo
H.M. Pinedo Vrije Universiteit Amsterdam
Marc Peeters
Marc Peeters University of Antwerp
Lisa Licitra
Lisa Licitra University of Milan
Patrick Pauwels
Patrick Pauwels University of Antwerp
Jos H. Beijnen
Jos H. Beijnen Utrecht University
Eric Van Marck
Eric Van Marck University of Antwerp
Ezra E.W. Cohen
Ezra E.W. Cohen University of California, San Diego
Alfio Ferlito
Alfio Ferlito University of Udine
Alessandra Rinaldo
Alessandra Rinaldo University of Udine
Robert I. Haddad
Robert I. Haddad Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medical careers but seeking flexible learning options, a range of online healthcare degrees are available. These programs help working professionals and career changers upskill quickly and affordably, providing alternative entry points into the medical field beyond traditional medical school.

Individuals aiming for healthcare leadership might consider the top cahme accredited mha programs. These online master’s degrees in healthcare administration are designed for those who want to lead in health systems, hospitals, or medical organizations.

Nurses can advance their credentials through online rn to bsn programs without clinicals. These programs offer academic flexibility and can be ideal for experienced RNs seeking to boost their qualifications from home.

Higher-level nursing degrees are also within reach. If time is a concern, the shortest online dnp program allows nurses to earn a Doctor of Nursing Practice efficiently. Cost-conscious students may prefer the cheapest dnp program to minimize tuition while maximizing their career options in advanced practice and leadership.

Best Scientists Citing Jan B. Vermorken

Trending Scientists

Recently Published Articles